News from Syndax Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 11, 2017, 15:00 ET Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Nov 07, 2017, 16:05 ET Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Nov 07, 2017, 08:00 ET Syndax to Present at the SITC 32nd Annual Scientific Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Oct 31, 2017, 07:00 ET Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Oct 17, 2017, 07:01 ET Syndax Announces $25 Million Registered Direct Offering of Common Stock

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Oct 17, 2017, 07:00 ET Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Oct 05, 2017, 07:00 ET Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Aug 30, 2017, 07:00 ET Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer...


Aug 10, 2017, 16:05 ET Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Aug 03, 2017, 07:00 ET Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017

Syndax (Nasdaq: SNDX) announced today that it will release its second quarter 2017 financial results on Thursday, August 10, 2017, after...


Jul 11, 2017, 16:05 ET Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Jan 20, 2016, 08:00 ET Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced...


Dec 03, 2015, 08:00 ET Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Dec 01, 2015, 08:00 ET Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Sep 16, 2015, 08:00 ET Syndax To Present At Two Upcoming Scientific Conferences

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Sep 01, 2015, 08:00 ET Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals As SVP And Chief Development Officer

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Feb 05, 2015, 12:00 ET Syndax to Present at 2015 BIO CEO & Investor Conference

 Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th...


Jan 07, 2015, 19:00 ET Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

 Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax...


May 27, 2014, 08:00 ET Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

 Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual...


Mar 27, 2014, 18:43 ET Syndax Files Registration Statement for Proposed Initial Public Offering

 Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...


Feb 13, 2014, 08:00 ET Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has...


Nov 01, 2013, 08:00 ET Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and...


May 14, 2013, 08:30 ET Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers...


May 29, 2012, 08:30 ET Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO

 Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized,...


May 16, 2012, 08:30 ET Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...